MAY & BAKER LIMITED
Get an alert when MAY & BAKER LIMITED files next
Leroy will email you the moment a new filing lands at Companies House — one short note per filing, nothing else.
Next accounts due
2026-09-30 (in 4mo)
Last filed for 2024-12-31
Confirmation statement due
2027-01-14 (in 8mo)
Last made up 2025-12-31
Watchouts
None on the register
Cash
—
Latest balance sheet
Net assets
£9M
+5.5% vs 2023
Employees
—
Average over period
Profit before tax
£629K
+24.3% vs 2023
Name history
Renamed 2 times since incorporation
- MAY & BAKER LIMITED 1991-12-16 → present
- MAY & BAKER PHARMACEUTICALS LIMITED 1991-03-20 → 1991-12-16
- FIGCROFT LIMITED 1989-12-07 → 1991-03-20
Net assets
2-year trend · vs Industrials median
Accounts
2-year trend · latest reflected 2024-12-31
| Metric | Trend | 2023-12-31 | 2024-12-31 |
|---|---|---|---|
| Turnover | — | — | |
| Operating profit | -£13,000 | £106,000 | |
| Profit before tax | £506,000 | £629,000 | |
| Net profit | £403,000 | £472,000 | |
| Cash | — | — | |
| Total assets less current liabilities | £9,241,000 | £9,713,000 | |
| Net assets | £8,585,000 | £9,057,000 | |
| Equity | £8,585,000 | £9,057,000 | |
| Average employees | — | — | |
| Wages | — | — |
Values shown as filed in the company's annual accounts. — indicates the figure wasn't present under that line item in that period. About these numbers
Ratios
Computed from the line items above — sparklines read oldest → newest
| Ratio | Trend | 2023-12-31 | 2024-12-31 |
|---|---|---|---|
| Return on capital employed | -0.1% | 1.1% | |
| Current ratio | 3.07x | 6.17x |
Margins divide P&L lines by turnover. Gearing is liabilities over total assets. Current ratio is current assets over creditors falling due within one year. Interest cover is operating profit over absolute finance costs. Sector-distribution context coming next.
Audit & accounting basis
- Accounting basis
- FRS 101
- Reporting scope
- Standalone (parent only)
- Auditor
- Forvis Mazars LLP
- Audit opinion
- Unqualified (clean)
- Going concern
- Affirmed
“The company is in a net asset position of £9.1m and made a profit of £0.5m. Having considered the plans in place and having reviewed cashflow forecasts, the Directors consider the adoption of the going concern basis on preparing these financial statements is appropriate. Furthermore, the Directors have received confirmation from Sanofi S.A., the ultimate parent company, confirming their ability to support the Company to 31 December 2026.”
Auditor, going-concern and subsidiary information is drawn from the narrative of the latest annual accounts. About these numbers
People
2 active · 35 resigned
| Name | Role | Appointed | Born | Nationality |
|---|---|---|---|---|
| MOHAMED, Walaa Mostafa Abbas Awad | Director | 2026-02-01 | Oct 1977 | Egyptian |
| MOUSSA, Ahmed Mohamed Moustafa | Director | 2026-02-01 | Aug 1984 | Egyptian |
Show 35 resigned officers
| Name | Role | Appointed | Resigned |
|---|---|---|---|
| CLAPHAM, Christopher Edward | Secretary | 2000-02-18 | 2001-06-30 |
| HARRIS, Michael John | Secretary | — | 1996-10-04 |
| MCCLELLAN, Michael James | Secretary | 2008-02-13 | 2010-05-12 |
| NICHOLLS, David John | Secretary | 2001-06-30 | 2004-02-25 |
| NICHOLLS, David John | Secretary | 1996-10-04 | 2000-02-18 |
| ROBERTS, Helen | Secretary | 2004-12-20 | 2008-01-30 |
| SMITH, Suzanne Elaine | Secretary | 2004-02-23 | 2004-12-20 |
| ABREHART, David Charles | Director | 1999-10-01 | 2000-01-13 |
| ALLINGTON, Timothy James | Director | — | 1998-05-20 |
| AULAGNON, Marie-Christine Gisele | Director | 1997-04-07 | 1999-10-01 |
| BAIRD, Jessamy Rachel | Director | 2021-08-19 | 2024-03-01 |
| BERTRAND, Jean-Jacques, Monsieur | Director | — | 1995-02-28 |
| BLINMAN, Peter | Director | 1993-12-14 | 1997-04-30 |
| BROOKSBY, Nigel Stanley | Director | 2004-11-08 | 2010-05-12 |
| CHANCEL, Pierre | Director | 2004-05-19 | 2004-11-08 |
| COLQUHOUN, Richard Lyons | Director | — | 1997-12-04 |
| DE FORCEVILLE, Guillaume Adrien | Director | 2004-11-08 | 2007-11-16 |
| DUHALDE, Francois-Xavier | Director | 2016-04-01 | 2021-03-31 |
| FRY, Hugo Rupert Alexander | Director | 2017-01-01 | 2021-03-31 |
| HARRIS, Michael John | Director | 1993-02-01 | 1996-10-04 |
| HEMINGWAY, Roger Barry | Director | 1998-05-18 | 2000-03-24 |
| KHAN, Usman | Director | 2021-03-31 | 2026-02-01 |
| MCCLELLAN, Michael James | Director | 2007-11-16 | 2010-10-01 |
| MICHELMORE, John Douglas | Director | — | 1999-01-31 |
| MITCHUM, James Paul | Director | 1999-12-16 | 2002-12-13 |
| NICHOLLS, David John | Director | 1996-10-04 | 2004-11-08 |
| OLDFIELD, Stephen Philip | Director | 2010-05-12 | 2014-07-25 |
| PROSSER, Andrew Michael James | Director | 2010-09-01 | 2016-04-01 |
| REES, David Hugh Thomas | Director | 2000-01-10 | 2004-11-08 |
| SALENGER, Keith Philip | Director | 1993-02-01 | 1994-03-31 |
| STANTON, Frances Louise | Director | — | 1998-09-30 |
| STENVALL, Tarja Johanna | Director | 2014-11-19 | 2016-09-30 |
| TILLETT, Gordon Michael | Director | 2021-03-31 | 2021-08-19 |
| UBHI, Rippondeep | Director | 2024-03-01 | 2026-02-01 |
| WHELAN, Anthony John | Director | 2000-02-04 | 2003-09-12 |
Ownership
Persons with significant control
| Name | Kind | Nature of control | Notified | Status |
|---|---|---|---|---|
| Aventis Pharma Limited | Corporate entity | Shares 75–100%, Voting 75–100%, Appoints directors | 2021-01-25 | Active |
| Sanofi-Aventis Uk Holdings Limited | Corporate entity | Shares 75–100%, Voting 75–100%, Appoints directors | 2016-04-06 | Ceased 2021-01-25 |
Filing timeline
Last 20 of 213 total filings
| Date | Type | Category | Description | |
|---|---|---|---|---|
| 2026-02-05 | AP01 | officers | Appoint person director company with name date | |
| 2026-02-05 | TM01 | officers | Termination director company with name termination date | |
| 2026-02-05 | TM01 | officers | Termination director company with name termination date | |
| 2026-02-05 | AP01 | officers | Appoint person director company with name date | |
| 2026-01-05 | CS01 | confirmation-statement | Confirmation statement with no updates | |
| 2025-12-12 | AA | accounts | Accounts with accounts type full | |
| 2025-05-27 | RP04AP01 | officers | Second filing of director appointment with name | |
| 2025-05-19 | CH01 | officers | Change person director company with change date | |
| 2025-02-09 | CS01 | confirmation-statement | Confirmation statement with no updates | |
| 2024-10-14 | AA | accounts | Accounts with accounts type full | |
| 2024-03-03 | AP01 | officers | Appoint person director company with name date | |
| 2024-03-01 | TM01 | officers | Termination director company with name termination date | |
| 2024-02-02 | CS01 | confirmation-statement | Confirmation statement with no updates | |
| 2023-07-18 | AA | accounts | Accounts with accounts type full | |
| 2023-01-06 | CS01 | confirmation-statement | Confirmation statement with no updates | |
| 2022-07-15 | AA | accounts | Accounts with accounts type full | |
| 2022-02-07 | CS01 | confirmation-statement | Confirmation statement with no updates | |
| 2021-08-25 | AP01 | officers | Appoint person director company with name date | |
| 2021-08-20 | TM01 | officers | Termination director company with name termination date | |
| 2021-07-28 | AA | accounts | Accounts with accounts type full |
Public-record activity
Raw counts from Companies House — last 12–24 months
- Filings
- 8
- Capital events
- 0
- Officers appointed
- 2
- Officers resigned
- 2
last 12 months
last 24 months
last 12 months
last 12 months
Direct counts from the register. No score, no rating — see the Filing timeline for the underlying events.
Year-on-year
FY2023 → FY2024 · period ending 2024-12-31 vs 2023-12-31
-
Turnover
—
Not reported
-
Cash
—
Not reported
-
Net assets
+5.5%
£8,585,000 £9,057,000
-
Employees
—
Not reported
-
Operating profit
+915.4%
-£13,000 £106,000
-
Profit before tax
+24.3%
£506,000 £629,000
Each % is (latest − prior) ÷ |prior| for the line item as filed. The comparison is only shown when the latest and prior accounts cover broadly equal-length periods — short or long stubs (typical around incorporation or a year-end change) are suppressed rather than misrepresented. Lines a company doesn't report are omitted. About these numbers